TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35700209

Group type: EXPERIMENTAL
Intervention: Integrated WASH, MNCH, nutrition and ECD interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control site
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention site
Number of subjects: 0
Study: 33653118

Group type: EXPERIMENTAL
Intervention: Ezogabine (900 mg/day; N=21)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (N=24)
Number of subjects: 45
Study: 36274166

Group type: EXPERIMENTAL
Intervention: Plenum® Oss 3Dβ fit (alloplastic graft)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Autogenous bone graft
Number of subjects: 0
Study: 34186532

Group type: EXPERIMENTAL
Intervention: Isometric handgrip training (IHT) - 3 sessions per week for 8 weeks, consisting of 4 sets of isometric contractions for 2 min at 30% of maximum voluntary contraction.
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group received a compression ball for sham training.
Number of subjects: 53
Study: 33689525

Group type: EXPERIMENTAL
Intervention: lacto‐ovo‐vegetarian diet (LOV‐D)
Number of subjects: 75
Study: 33338441

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 antibody seropositivity in the general population
Number of subjects: 8902

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 antibody seropositivity in the high-risk population
Number of subjects: 8902
Study: 33073938

Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg every night for three months
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no pentoxifylline)
Number of subjects: 42
Study: 33122288

Group type: EXPERIMENTAL
Intervention: KIM-1
Number of subjects: 894

Group type: EXPERIMENTAL
Intervention: TNFR-1
Number of subjects: 894

Group type: EXPERIMENTAL
Intervention: TNFR-2
Number of subjects: 894

Group type: EXPERIMENTAL
Intervention: MCP-1
Number of subjects: 894

Group type: EXPERIMENTAL
Intervention: suPAR
Number of subjects: 894

Group type: EXPERIMENTAL
Intervention: YKL-40
Number of subjects: 894
Study: 32878112

Group type: EXPERIMENTAL
Intervention: Graduated walking program for 6 months
Number of subjects: 70

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 70
Study: 35216750

Group type: EXPERIMENTAL
Intervention: Closed-loop system (Diabeloop DBL4K)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Open-loop system (sensor-augmented pump therapy)
Number of subjects: 21
Study: 32386001

Group type: EXPERIMENTAL
Intervention: Early goal directed sedation (EGDS) with continuous intravenous infusion of dexmedetomidine (initial dose of 0.2 μg×kg‐1×min‐1) for 72 hours
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Early goal directed sedation (EGDS)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Standard sedation (STD) with intravenous bolus of propofol
Number of subjects: 105

Group type: COMPARATOR
Intervention: Standard sedation (STD)
Number of subjects: 105
Study: 34383143

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide (CP) at-home bleaching
Number of subjects: 40
Study: 34071401

Group type: EXPERIMENTAL
Intervention: Video emphasizing sexual impotence (n = 60)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Video emphasizing cognitive impairment (n = 72)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Video emphasizing long-term effects (cancer, cardiovascular disease, n = 68)
Number of subjects: 269
Study: 32520132

Group type: EXPERIMENTAL
Intervention: Expository lectures
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Low-fidelity simulator model
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: High-fidelity simulator model
Number of subjects: 90
Study: 32732777

Group type: EXPERIMENTAL
Intervention: Soccer training with blood flow restriction (STBFR)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Normal soccer training (ST)
Number of subjects: 19
Study: 32967799

Group type: EXPERIMENTAL
Intervention: Tezacaftor/ivacaftor
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67

Group type: COMPARATOR
Intervention: Ivacaftor
Number of subjects: 67
Study: 32223108

Group type: EXPERIMENTAL
Intervention: Qilin Pills (QLP), 6 g tid for 6 months
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo control, 6 g tid for 6 months
Number of subjects: 168
Study: 36458443

Group type: EXPERIMENTAL
Intervention: Test formulation (T) of apixaban 2.5 mg under fasting conditions
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Test formulation (T) of apixaban 2.5 mg under fed conditions
Number of subjects: 64

Group type: COMPARATOR
Intervention: Reference formulation (R) of apixaban 2.5 mg under fasting conditions
Number of subjects: 64

Group type: COMPARATOR
Intervention: Reference formulation (R) of apixaban 2.5 mg under fed conditions
Number of subjects: 64
Study: 34409637

Group type: EXPERIMENTAL
Intervention: Causally associated genes identified through PMR-Egger analysis.
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: Causally associated genes identified through Bayesian co-localization analysis.
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis.
Number of subjects: 552
Study: 32506498

Group type: EXPERIMENTAL
Intervention: Negative-pressure wound therapy (NPWT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sterile island dressing
Number of subjects: 40
Study: 34533034

Group type: EXPERIMENTAL
Intervention: Experimental strategy: 75 to 100 mg aspirin daily plus 90 mg ticagrelor twice daily for 1 month, followed by 23 months of ticagrelor monotherapy
Number of subjects: 15000

Group type: COMPARATOR
Intervention: Reference strategy: 75 to 100 mg aspirin daily plus either 75 mg clopidogrel daily (for SCAD) or 90 mg ticagrelor twice daily (for ACS) for 12 months, followed by aspirin monotherapy for 12 months
Number of subjects: 15000

Group type: EXPERIMENTAL
Intervention: Experimental strategy
Number of subjects: 15000

Group type: COMPARATOR
Intervention: Reference strategy
Number of subjects: 15000
Study: 32513294

Group type: EXPERIMENTAL
Intervention: Prednisolone (40 mg daily for 3 days, then tapered down over 6 weeks)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 90
Study: 33686445

Group type: EXPERIMENTAL
Intervention: Non-dermatologists
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Dermatologists
Number of subjects: 200
Study: 35348606

Group type: EXPERIMENTAL
Intervention: Intranasal ketamine
Number of subjects: 74

Group type: COMPARATOR
Intervention: Intravenous morphine
Number of subjects: 74
Study: 34420373

Group type: EXPERIMENTAL
Intervention: Colchicine (2-mg loading dose followed by 0.5 mg twice a day)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study: 33809168

Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF testing in 2018 and 2019
Number of subjects: 1940

Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF testing in Bukhara region
Number of subjects: 1940

Group type: EXPERIMENTAL
Intervention: Duration from initial visit to receiving results in Tashkent city
Number of subjects: 1940

Group type: EXPERIMENTAL
Intervention: Duration from initial visit to receiving results in Bukhara region
Number of subjects: 1940
Study: 32639465

Group type: EXPERIMENTAL
Intervention: Daptomycin (once-daily, age-adjusted doses)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Comparator (vancomycin, nafcillin or equivalent)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Daptomycin
Number of subjects: 146

Group type: COMPARATOR
Intervention: Comparator
Number of subjects: 146
Study: 34458925

Group type: EXPERIMENTAL
Intervention: 1% acetaminophen gel
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 2.5% acetaminophen gel
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 5% acetaminophen gel
Number of subjects: 17

Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 17
Study: 34455556

Group type: EXPERIMENTAL
Intervention: Rimegepant 75 mg as needed (PRN) for patients with 2-8 MMD
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Rimegepant 75 mg as needed (PRN) for patients with 9-14 MMD
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Rimegepant on a fixed every-other-day schedule plus as needed dose (QOD+PRN) for patients with 4-14 MMD
Number of subjects: 1800
Study: 32255205

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided betamethasone injection with hydrodissection (5 mL)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ultrasound-guided betamethasone injection without hydrodissection (2 mL)
Number of subjects: 20
Study: 33812699

Group type: EXPERIMENTAL
Intervention: Ibuprofen (arginine)/tramadol 400/37.5 mg
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg alone
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Ibuprofen arginine 400 mg alone
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 33257486

Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring (rt-CGM)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Self-monitored blood glucose (SMBG)
Number of subjects: 372
Study: 36243225

Group type: EXPERIMENTAL
Intervention: Shockable rhythm
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Non-shockable rhythm
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Invasive treatment (n = 124) with shockable rhythm
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Invasive treatment (n = 124) with non-shockable rhythm
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Standard treatment (n = 132) with shockable rhythm
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Standard treatment (n = 132) with non-shockable rhythm
Number of subjects: 256
Study: 33929523

Group type: EXPERIMENTAL
Intervention: CMR (Comprehensive Medication Review)
Number of subjects: 2637

Group type: EXPERIMENTAL
Intervention: CMR plus postdischarge follow-up
Number of subjects: 2637

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2637
Study: 34844995

Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sensor-augmented pump therapy
Number of subjects: 30
Study: 36198259

Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Number of subjects: 109

Group type: COMPARATOR
Intervention: valsartan
Number of subjects: 109
Study: 34127260

Group type: COMPARATOR
Intervention: Pair housing (C)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Individual housing (I)
Number of subjects: 66
Study: 33242783

Group type: EXPERIMENTAL
Intervention: Good stroke knowledge for action (defined as recognition of impaired strength, sensation, and language plus intention to seek urgent medical attention in a hypothetical stroke situation)
Number of subjects: 1986

Group type: EXPERIMENTAL
Intervention: Good stroke knowledge for action
Number of subjects: 1986
Study: 32466773

Group type: EXPERIMENTAL
Intervention: 250 mg magnesium oxide plus 150 mg zinc sulfate for 12 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 60
Study: 35623045

Group type: EXPERIMENTAL
Intervention: Financial and social support systems, such as governmental and school resources
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Faculty members' flexibility and students' experience with online learning
Number of subjects: 38
Study: 33536010

Group type: COMPARATOR
Intervention: Ozone (3 doses weekly)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Hyaluronic Acid (HA) (3 doses weekly)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Platelet Rich Plasma (PRP) (2 doses with 3 weeks interval)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Plasma Rich in Growth Factors (PRGF) (2 doses with 3 weeks interval)
Number of subjects: 238
Study: 32216964

Group type: EXPERIMENTAL
Intervention: Controlled low central venous pressure
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 146
Study: 35133411

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 8144

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 8144

Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 8144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8144

Group type: EXPERIMENTAL
Intervention: Combination of medication and behavioral counseling
Number of subjects: 8144
Study: 34074584

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg−1.kg−1 body mass)
Number of subjects: 10
Study: 32011156

Group type: EXPERIMENTAL
Intervention: Language learning (Italian) for 11 weeks
Number of subjects: 160

Group type: COMPARATOR
Intervention: Relaxation training for 11 weeks
Number of subjects: 160
Study: 33712389

Group type: EXPERIMENTAL
Intervention: RARC with iUD
Number of subjects: 51

Group type: COMPARATOR
Intervention: ORC
Number of subjects: 51
Study: 33420720

Group type: EXPERIMENTAL
Intervention: HHV-6 serology in patients with COVID-19 and cutaneous manifestations
Number of subjects: 12

Group type: COMPARATOR
Intervention: HHV-6 serology in hospitalized patients with COVID-19 without cutaneous manifestations
Number of subjects: 12
Study: 34275099

Group type: EXPERIMENTAL
Intervention: Incretin-based therapy (sitagliptin followed by liraglutide)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 249
Study: 35794140

Group type: COMPARATOR
Intervention: VIBE-based single-artery phase imaging (Group A, n=50)
Number of subjects: 140

Group type: COMPARATOR
Intervention: StarVIBE (Group B, n=44)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: CAIPIRINHA-Dixon-TWIST-VIBE (CDT-VIBE)-based multi-artery phase imaging (Group C, n=46)
Number of subjects: 140
Study: 34266320

Group type: EXPERIMENTAL
Intervention: Patients with SLE
Number of subjects: 227

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 227
Study: 34472504

Group type: EXPERIMENTAL
Intervention: Arterolane maleate (AM) 37.5 mg and piperaquine phosphate (PQP) 187.5 mg
Number of subjects: 164

Group type: COMPARATOR
Intervention: Chloroquine phosphate
Number of subjects: 164
Study: 34656406

Group type: EXPERIMENTAL
Intervention: Telemedicine (TM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 0
Study: 33144299

Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular vagus nerve stimulation (taVNS)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham stimulation (SS)
Number of subjects: 18
Study: 32887564

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) - 4 sessions by trained nurses
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Standard geriatric rehabilitation alone
Number of subjects: 272
Study: 33070154

Group type: EXPERIMENTAL
Intervention: JNJ‐42165279 (25 mg daily)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 149
Study: 32657195

Group type: EXPERIMENTAL
Intervention: Linked color imaging (LCI)
Number of subjects: 1278

Group type: COMPARATOR
Intervention: HD white-light colonoscopy (WLC)
Number of subjects: 1278
Study: 35752551

Group type: EXPERIMENTAL
Intervention: HA+C Group (Hyaluronic Acid plus Corticosteroid)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Corticosteroid Group (Isolated Corticosteroid)
Number of subjects: 25
Study: 33372523

Group type: EXPERIMENTAL
Intervention: Resting LA reservoir strain (LASr)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Exercise E/e’
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Model combining LASr and clinical metrics
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Resting echocardiographic parameters (E/e’, LASr, LA contractile strain)
Number of subjects: 218
Study: 34420037

Group type: EXPERIMENTAL
Intervention: Enzalutamide plus ADT (n=574)
Number of subjects: 1150

Group type: COMPARATOR
Intervention: Placebo plus ADT (n=576)
Number of subjects: 1150
Study: 35126199

Group type: EXPERIMENTAL
Intervention: High-intensity exercise
Number of subjects: 52

Group type: COMPARATOR
Intervention: Low-intensity exercise
Number of subjects: 52
Study: 33162202

Group type: EXPERIMENTAL
Intervention: Oral pentavalent rotavirus vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maternal antibodies
Number of subjects: 0
Study: 33727659

Group type: EXPERIMENTAL
Intervention: 0.1% bromfenac sodium ophthalmic solution
Number of subjects: 26

Group type: COMPARATOR
Intervention: 0.02% fluorometholone ophthalmic suspension
Number of subjects: 26
Study: 36279020

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 33532885

Group type: EXPERIMENTAL
Intervention: Corifollitropin-α late-start (day 4)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard administration (day 2)
Number of subjects: 0
Study: 32419549

Group type: EXPERIMENTAL
Intervention: Higher graft CD34+ cell content (>2.5 × 10^6/kg)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Higher graft CD34+CD133+CD38– counts (>0.08 × 10^6/kg)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Higher infused CD3+CD4+ cell count (>37 × 10^6/kg)
Number of subjects: 129
Study: 34713371

Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted surgery
Number of subjects: 468

Group type: COMPARATOR
Intervention: Open resection
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 468
Study: 34252034

Group type: EXPERIMENTAL
Intervention: Virtual Operating Room Tour (VORT)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Standard operation preparation procedure
Number of subjects: 84
Study: 35956425

Group type: EXPERIMENTAL
Intervention: Dyadic, Web-Based, Weight Loss Intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group measures
Number of subjects: 0
Study: 33710344

Group type: EXPERIMENTAL
Intervention: Protein-polyphenol (PP) drinks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Isocaloric maltodextrin placebo (PLA) drinks
Number of subjects: 18
Study: 36070825

Group type: EXPERIMENTAL
Intervention: Novel 3D-printed custom tray
Number of subjects: 15

Group type: COMPARATOR
Intervention: Conventional impression tray
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Diagnostic denture impression
Number of subjects: 15

Group type: COMPARATOR
Intervention: Conventional impression
Number of subjects: 15
Study: 32606097

Group type: EXPERIMENTAL
Intervention: Chemotherapy (paclitaxel weekly or pegylated liposomal doxorubicin) + bevacizumab + atezolizumab
Number of subjects: 664

Group type: COMPARATOR
Intervention: Chemotherapy (paclitaxel weekly or pegylated liposomal doxorubicin) + bevacizumab + placebo
Number of subjects: 664
Study: 33802559

Group type: EXPERIMENTAL
Intervention: Progressive dynamic balance training (PDBT) with physical therapy
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (physical therapy only)
Number of subjects: 38
Study: 32976938

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg/Q3W)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Single-agent chemotherapy (gemcitabine or vinorelbine)
Number of subjects: 144
Study: 33681651

Group type: EXPERIMENTAL
Intervention: Perampanel
Number of subjects: 1121
Study: 32521745

Group type: EXPERIMENTAL
Intervention: High Intensity Interval Resistance Training (HIIRT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional Resistance Training (TRT)
Number of subjects: 20
Study: 33319755

Group type: EXPERIMENTAL
Intervention: Early pregnancy treatment (nutrition counseling, glucose monitoring, medications as needed)
Number of subjects: 157
Study: 35712968

Group type: EXPERIMENTAL
Intervention: HIPEC (n=92)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Control (n=92)
Number of subjects: 184
Study: 32390123

Group type: EXPERIMENTAL
Intervention: Simulated sunlight (1.3× standard-erythema dose, 3×/week for 4 weeks and then 1×/week for 8 weeks)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Oral vitamin D3 (1000 IU/day for 4 weeks and 400 IU/day for 8 weeks)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Low vitamin D status (25(OH)D ≤ 40 vs 41-71 nmol/L)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Low vitamin D status (1,25(OH)2D ≤ 120 vs ≥ 157 pmol/L)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Winter vaccination vs summer vaccination
Number of subjects: 119
Study: 36428098

Group type: EXPERIMENTAL
Intervention: UC+MI
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: UC+SVAI
Number of subjects: 514

Group type: COMPARATOR
Intervention: UC
Number of subjects: 514
Study: 34036321

Group type: EXPERIMENTAL
Intervention: 24-hour urinary sucrose and fructose (24uSF) biomarker
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Calibration of the biomarker
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Calibrated biomarker based on a single measurement
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Calibrated biomarker based on 4 repeats
Number of subjects: 98
Study: 33067279

Group type: EXPERIMENTAL
Intervention: Sulforaphane treatment for 12 weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo treatment for 12 weeks
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Sulforaphane treatment
Number of subjects: 90
Study: 35192016

Group type: EXPERIMENTAL
Intervention: 3% Hypertonic Saline (3% HTS)
Number of subjects: 93

Group type: COMPARATOR
Intervention: 0.9% Saline (NS)
Number of subjects: 93
Study: 33006504

Group type: EXPERIMENTAL
Intervention: Ethanolic extract of Opuntia ficus-indica var. saboten (OFE) administered for 12 weeks
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 35617960

Group type: EXPERIMENTAL
Intervention: Informational video
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standard informed consent process
Number of subjects: 82
Study: 33487626

Group type: EXPERIMENTAL
Intervention: Participatory workplace improvement program
Number of subjects: 31
Study: 32737350

Group type: EXPERIMENTAL
Intervention: Exercise with LCPUFA (docosahexaenoic acid 300 mg/day, eicosapentaenoic acid 100 mg/day, arachidonic acid 120 mg/day)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76

Group type: COMPARATOR
Intervention: No exercise with placebo
Number of subjects: 76
Study: 34776140

Group type: EXPERIMENTAL
Intervention: Blood flow restriction (BFR) exercise program
Number of subjects: 26

Group type: COMPARATOR
Intervention: Non-BFR control group (CG)
Number of subjects: 26
Study: 36202586

Group type: EXPERIMENTAL
Intervention: Milk protein concentrate (MPC) supplementation
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 44